Zhang M, et al. - Researchers gauged the relationship between MET amplification, protein or mRNA expression, and mutations in colorectal cancer (CRC). The MET immunohistochemistry (IHC) was used for MET protein expression analysis and fluorescence in situ hybridization (FISH) was used for MET amplification detection. It was noted that MET mRNA expression was upregulated in tumor tissues compared with the adjacent normal tissues. The incidence of MET amplification appeared to be 4.4%. Neither of the patients displayed positive results for MET mutation. Data indicated that MET was overexpressed in colorectal adenocarcinoma, and its positive protein expression speculated a poorer outcome in CRC patients. MET amplification and 14 exon mutation were discovered to be extremely rare events in colorectal adenocarcinoma.